AKT1 and cancer: This confirms previous results from pharmacodynamic analysis of cancer patient–derived tumor material showed increased AKT S473 phosphorylation in some cases [50,51] after treatment with doses and schedules of EVE defined as biologically optimal through pharmacokinetic/pharmacodynamic modeling of preclinical and phase I data [52-54].